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A B S T R A C T
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is increasingly
used in patients with advanced melanoma. Immune checkpoint inhibitors and BRAF/MEK-targeted therapy have
transformed the therapeutic landscape of metastatic melanoma. Consequently, a need for markers predicting
(early) response to treatment and for monitoring treatment (toxicity) has arisen. This systematic review ap-
praises the current literature evidence for rational use of 18F-FDG PET/CT scans in staging, clinical decision-
making, treatment monitoring and follow-up in advanced melanoma. 18F-FDG PET/CT has high overall accuracy
for detection of distant metastases and is, combined with cerebral MRI, the preferred imaging strategy for
staging metastatic melanoma. In contrast, strong evidence supporting the standard use of 18F-FDG PET/CT for
predicting and monitoring therapy response and toxicity is currently lacking. Essential for determining the
position of 18F-FDG PET/CT during treatment course in advanced melanoma are well-designed studies with
standardized scanning protocols, incorporation of clinical parameters and comparison with contrast-enhanced
CT alone.
1. Introduction
Immune checkpoint inhibitors and targeted therapy with small
molecule inhibitors have markedly improved the prognosis of meta-
static melanoma, with five-year overall survival (OS) rates as high as 52
% in patients treated with the combination of the immune checkpoint
inhibitors ipilimumab and nivolumab (Larkin et al., 2019). Patients
with metastases in more than two organs and high tumour burden have
worse response to therapy and lower survival rates, emphasizing the
importance of adequate and early detection of metastases for proper
treatment selection (Nakamura et al., 2016; Long et al., 2016).
Positron emission tomography (PET) using the radioactively la-
belled glucose analogue 18F-fluorodeoxyglucose (18F-FDG) visualizes
glucose uptake, which enables the identification of tumours based on
their increased glucose metabolism compared to most normal tissues. In
contrast, conventional imaging modalities used in oncology, such as
contrast-enhanced computed tomography (ce-CT), magnetic resonance
imaging (MRI) and ultrasound (US), are most commonly used to obtain
structural information. 18F-FDG PET scanning is routinely combined
with low-dose CT scanning (18F-FDG PET/CT) to obtain attenuation
corrected PET images and improve specificity and accuracy by
providing anatomical information.
For early stage melanoma patients (stage I and II), 18F-FDG PET/CT
has a low yield for detection of distant metastases (Veit-Haibach et al.,
2009; Mena et al., 2016; Wagner et al., 2012). The evidence in ad-
vanced melanoma is more variable and melanoma guidelines provide
different recommendations regarding clinical indications for 18F-FDG
PET/CT in this setting (Suppl. Table 1) (Australian Cancer Network
Melanoma Guidelines Revision Working Party, 2008; Michielin et al.,
2019; Coit et al., 2019). Moreover, novel clinical questions regarding
the value of 18F-FDG PET/CT have arisen following the introduction of
targeted therapy and immunotherapy for advanced melanoma. It is
important to determine the value of 18F-FDG PET/CT in patient selec-
tion, response and toxicity monitoring and follow-up of patients with an
ongoing response. Quantitative 18F-FDG measurements, such as stan-
dardized uptake value (SUV) and metabolically active tumour volume
(MTV), can predict prognosis and treatment response in other malig-
nancies, including metastatic non-small cell lung cancer and lym-
phoma, and are increasingly under investigation in melanoma
(Kahraman et al., 2011; Meignan et al., 2016; Kim et al., 2013; Liao
et al., 2012). Advances in conventional imaging techniques and new
techniques such as whole-body (wb) (PET/)MRI might also alter the
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previously established role of 18F-FDG PET/CT (Fraum et al., 2016).
The aim of this systematic review is to provide a critical overview of the
available evidence on the role of 18F-FDG PET/CT imaging in staging,
monitoring of therapy and follow-up of advanced melanoma.
2. Methods
2.1. Article selection
The EMBASE and MEDLINE databases were systematically searched
for relevant articles published between January 2000 (first FDA ap-
proval of integrated PET/CT (Townsend et al., 2004)) and January
2020 using the terms “melanoma” and “fluorodeoxyglucose f 18 or fdg
or fluorodeoxyglucose or 18fdg or 2 fluoro 2 deoxy”, including the
expanded Emtree terms “melanoma” and “fluorodeoxyglucose f 18”
(see Suppl. File 1 for the full search strings). Conference abstracts were
excluded. Eligibility screening of titles and abstracts and subsequent
full-text assessment of the eligible articles were performed by two au-
thors (CB, ECH). Articles were excluded in case of non-English lan-
guage, inaccessibility of the full text, preclinical research, commen-
taries, non-cutaneous melanoma, no stage IV or advanced melanoma,
non-18F-FDG PET tracers and/or use of only 18F-FDG PET scanning (i.e.
without concurrent CT) (Suppl. Fig. 1). Disagreements on article se-
lection were resolved through discussion until consensus was reached.
Article references were additionally checked for relevant studies not
identified by the database search, and current guidelines for melanoma
and nuclear imaging in oncology were consulted. The international
clinical trial registry ClinicalTrials.gov was searched in January 2020
for unpublished studies (updated<5 years ago) on 18F-FDG PET/CT in
stage IV melanoma. Levels of Evidence (LoE) of listed studies were
determined using the Oxford 2011 Levels of Evidence, v2.1 (OCEBM
Levels of Evidence Working Group, 2011).
2.2. Terminology
This review appraises studies using integrated 18F-FDG PET/CT
scanning, i.e. studies that involve 18F-FDG PET scanning with at least
low-dose, non-contrast-enhanced CT (ld-/nce-CT) scanning. PET only
studies were excluded. When the term 18F-FDG PET is used, this in-
dicates study results that have been described to be interpreted solely
based on the 18F-FDG PET part of 18F-FDG PET/CT scans. ce-CT refers
to CT scans obtained for diagnostic purposes using higher radiation
doses and intravenously administered contrast. In sections where the
term 18F-FDG PET/ce-CT is explicitly used, this refers to a study un-
equivocally describing the use of ce-CT in its methods.
3. 18F-FDG PET/CT in detection of distant melanoma metastases
Although 18F-FDG PET/CT is most commonly utilized in patients
with advanced stage melanoma, the majority of studies have focused on
detecting melanoma metastases by 18F-FDG PET(/CT) in the clinically
non-metastatic setting. Twenty–two studies that investigated the de-
tection of distant metastases by 18F-FDG PET/CT were identified by our
search (Suppl. Table 2) (Veit-Haibach et al., 2009; Mena et al., 2016;
Wagner et al., 2012; Xing et al., 2011; Pfluger et al., 2011; Pfannenberg
et al., 2007; Laurent et al., 2010; Jouvet et al., 2014; Mottaghy et al.,
2007; Aukema et al., 2010; Abbott et al., 2011; Bastiaannet et al., 2012;
Gellén et al., 2015; Eldon et al., 2017; Rodriguez Rivera et al., 2014;
Madu et al., 2017; Lewin et al., 2018; Reinhardt et al., 2006a; Leon-
Ferre et al., 2017; Koskivuo et al., 2016; Vensby et al., 2017; Lee et al.,
2018). In stage III, sensitivity of 18F-FDG PET/CT in detecting distant
melanoma metastases during follow-up ranged between 82 % and 100
% and the specificity ranged between 45 % and 100 % (Pfluger et al.,
2011; Pfannenberg et al., 2007; Mottaghy et al., 2007; Aukema et al.,
2010; Abbott et al., 2011; Bastiaannet et al., 2012; Gellén et al., 2015;
Eldon et al., 2017; Rodriguez Rivera et al., 2014; Madu et al., 2017;
Reinhardt et al., 2006a, a; Leon-Ferre et al., 2017; Koskivuo et al., 2016;
Vensby et al., 2017). Sensitivity within stage III patients increases from
stage IIIa to IIIc (American Joint Committee on Cancer 7th edition),
although negative predictive value is high across all substages (80 %)
(Lewin et al., 2018). The performance of 18F-FDG PET/CT in detection
of melanoma metastases compared to other specific imaging modalities
is discussed below.
3.1. 18F-FDG PET/CT versus contrast-enhanced CT
Most centres consider ce-CT of chest and abdomen (with brain MRI)
as the standard imaging procedure for detection of stage IV melanoma.
The performance of 18F-FDG PET/CT vs CT was studied in a detailed
meta-analysis on imaging modalities in melanoma, which included 13
18F-FDG PET/CT (1030 patients) and 13 CT studies (1320 patients)
(Xing et al., 2011). All included studies involved> 10 patients and
lesions identified by imaging were confirmed by histology or follow-up
imaging studies at least six months after identification. When con-
sidering primary staging of stage IV melanoma, overall estimates for
sensitivity of 18F-FDG PET/CT vs CT were 80 % vs 51 % and 87 % vs 69
% for specificity. However, both studies with ce-CT and nce-CT in
combination with 18F-FDG PET were regarded as 18F-FDG PET/CT in
this meta-analysis (Veit-Haibach et al., 2009; Xing et al., 2011). Sen-
sitivity of regular 18F-FDG PET/CT might thus have been overestimated.
A more recent study in 50 patients with metastatic melanoma indeed
reports less false-negative results by 18F-FDG PET/ce-CT than 18F-FDG
PET/nce-CT (Pfluger et al., 2011). Nevertheless, the superiority of 18F-
FDG PET/CT over ce-CT for detection of metastases was confirmed,
with a sensitivity of 97 vs 85 % and specificity of 93 vs 63 %. The false-
negative findings did not affect staging results (Pfluger et al., 2011).
Overall, 18F-FDG PET/CT outperforms ce-CT for staging stage IV mel-
anoma when considering all possible disease locations. The lower ra-
diation exposure of 18F-FDG PET/ld-CT compared to ce-CT (approxi-
mately 5–10 mSv vs. 15–20 mSv (Boellaard et al., 2015; Li et al., 2019;
Smith-Bindman et al., 2019)) provides an additional advantage.
3.2. 18F-FDG PET/CT versus whole-body MRI
Brain MRI is part of the standard work-up in stage IV melanoma.
Whole-body MRI (wb-MRI), in contrast, is a relatively new imaging
modality in advanced melanoma, both as a standalone imaging method
as well as when integrated with PET. An advantage of wb-MRI over CT
is the lack of exposure to ionizing radiation. Studies comparing the
performance of wb-MRI to 18F-FDG PET/(ce-)CT in advanced mela-
noma have varying outcomes (Pfannenberg et al., 2007; Laurent et al.,
2010; Jouvet et al., 2014; Ciliberto et al., 2013; Berzaczy et al., 2020).
In a prospective study in 35 patients with advanced melanoma, sensi-
tivity of wb-MRI for detection of melanoma metastases was higher than
18F-FDG PET/CT (82 % vs. 72.8 %) (Laurent et al., 2010). Two other
studies with a comparable design (n = 37 and 64 respectively) also
reported a higher or similar sensitivity of wb-MRI compared to 18F-FDG
PET/CT with a similar specificity (Pfannenberg et al., 2007; Jouvet
et al., 2014). The diagnostic accuracy differed between anatomical lo-
cations of metastases: wb-MRI was more accurate in detecting metas-
tases in liver, bone and brain, whereas 18F-FDG PET/CT was more ac-
curate in detecting lymph node and (sub)cutaneous metastases
(Pfannenberg et al., 2007). In contrast, two more recent studies could
not find any metastatic site-specific differences in diagnostic accuracy
of wb-MRI and 18F-FDG PET/CT (Jouvet et al., 2014; Heusner et al.,
2011). The lack of unequivocal evidence that wb-MRI leads to better
patient staging than 18F-FDG PET/CT, its high costs and limited avail-
ability make it unlikely that wb-MRI will replace 18F-FDG PET/CT in
the near future.
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3.3. 18F-FDG PET/CT for detection of melanoma metastases in specific
locations
3.3.1. Lymph nodes
Ultrasound (US) is the preferred imaging modality for staging of
locoregional lymph nodes in stage III melanoma due to its higher ac-
curacy compared to 18F-FDG PET/CT (Xing et al., 2011). A meta-ana-
lysis evaluated the performance of US and 18F-FDG PET/CT in detecting
melanoma lymph node metastases during respectively primary staging
and surveillance (Xing et al., 2011). During primary staging, sensitivity
was 60 % for US vs 11 % for 18F-FDG PET/CT and during surveillance
respectively 96 % vs 65 %. Both imaging modalities had an equal
specificity of 97–99 % in these two settings (Xing et al., 2011). A more
recent prospective study in 37 melanoma patients demonstrated that
18F-FDG PET/CT has an equal sensitivity (100 %) and lower specificity
than US (95 % vs 100 %) for superficial lymph node detection in stage
IV patients, but this was based on only 13 melanoma-positive lymph
nodes (Jouvet et al., 2014). Compared to ce-CT, 18F-FDG PET/CT
maximum standardized uptake value (SUVmax) above 2.4 had the
highest sensitivity (91 %) and accuracy (89 %) for detection of regional
lymph node metastases ≥1 cm in a retrospective study (Cha et al.,
2018).
3.3.2. Lung
Ce-CT has a higher sensitivity than 18F-FDG PET/CT for lung me-
tastases (Fig. 1). Lung lesions smaller than 11 mm are frequently missed
by 18F-FDG PET (Pfannenberg et al., 2007; Jouvet et al., 2014;
Reinhardt et al., 2006b). In a retrospective study, no lung lesions
smaller than five mm on the nce-CT of an 18F-FDG PET/CT scan were
PET positive (Reinhardt et al., 2006b). Sensitivity increased size-de-
pendently from 38.8 % to 87.5 % in 5–13 mm-sized lesions and reached
100 % in lesions ≥14 mm. The addition of ce-CT to the 18F-FDG PET
increased its sensitivity from 26.4 % to 96.2 % for lung metastases in
melanoma, however the high false-positive rate of pulmonary findings
on CT resulted in a low specificity (35.3 %) (Pfannenberg et al., 2007).
3.3.3. Brain
Up to 50 % of the patients with advanced melanoma develop brain
metastases (Davies et al., 2011). These metastases may require (ste-
reotactic) radiotherapy or surgery to gain local control. Brain imaging is
therefore important in advanced melanoma. Detection of brain metas-
tases by 18F-FDG PET/CT is limited by the high 18F-FDG uptake of
normal brain tissue and low spatial resolution of 18F-FDG PET, making
MRI the preferred brain imaging modality (Ludwig et al., 2002) (Fig. 1).
In a prospective analysis, 15 of 64 patients with advanced melanoma
had cerebral metastases diagnosed by MRI that could not be detected on
the 18F-FDG PET/CT scan (Pfannenberg et al., 2007). MRI provides
better soft tissue contrast resolution than ce-CT and can detect smaller
brain metastases (Laurent et al., 2010).
3.3.4. Bowel
Melanoma commonly metastasizes to the gastro-intestinal tract,
predominantly the small bowel. 18F-FDG PET detection of gastro-in-
testinal metastases can be complicated by physiological gastro-in-
testinal 18F-FDG uptake. In cases where confirmed diagnosis of bowel
metastases would change the therapeutic strategy, (capsule) endoscopy
can be considered (Goenka et al., 2014; Bender et al., 2001). This may
be preceded by 18F-FDG PET/CT to guide the initial endoscopic ap-
proach towards a specific bowel segment. A prospective study reported
increased bowel 18F-FDG uptake in 12/21 patients with stage IV mel-
anoma (Prakoso et al., 2011). Capsule endoscopy confirmed small-
bowel metastases in only five of these patients. A possible explanation is
a submucosal or exo-enteric localization of bowel metastases, which
impedes detection by endoscopy. Furthermore, it was not specified
whether the increased bowel 18F-FDG uptake in these 12 patients was
diffuse, i.e. likely due to non-malignant causes, or focal, i.e. more sus-
picious of malignancy. Such differentiation is essential to minimize the
rate of false-positive results for bowel 18F-FDG uptake.
3.3.5. Bone and soft tissue
Adequate diagnosis of melanoma bone metastasis enables timely
local therapy (e.g. radiotherapy) to relieve pain and to prevent frac-
tures. 18F-FDG PET/CT scanning outperforms ce-CT in the detection of
bone metastases (Fig. 1) (Pfannenberg et al., 2007; Jouvet et al., 2014;
Bier et al., 2016). Lesion-based sensitivity for bone metastases was only
36.8 % for ce-CT compared to 18F-FDG PET/CT as a reference (Bier
Fig. 1. Examples of detection of melanoma metastases (arrows) in specific locations by 18F-FDG PET/CT compared to ce-CT or MRI (brain). (Patient drawing adjusted
from Wikimedia Commons [Internet] (2020)).
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et al., 2016). Nevertheless, isolated musculoskeletal 18F-FDG-avid sites
have a low positive predictive value for melanoma (31 %), even after
excluding lesions that were unsuspicious based on additional clinical or
CT information, as was shown in a retrospective study in 342 patients
with stage IIb-IV melanoma (Mansour et al., 2010). The relative risk
(RR) for a false-positive musculoskeletal 18F-FDG-avid site was higher
when no other metastases were present on the 18F-FDG PET/CT scan
(RR 5.33 [95 % CI 2.85–9.94]).
Bone and soft tissue metastases can be localized throughout the
body and can thus be missed when the 18F-FDG PET/CT field of view
(FOV) only includes the torso. Torso 18F-FDG PET/CT scanning di-
minishes scan duration, which has practical advantages, is more pa-
tient-friendly and diminishes the risk of movement artefacts. Several
studies in stage III and IV melanoma have compared true whole-body
imaging (i.e. from top of the head to the feet) to torso imaging (i.e. from
the base of the skull to the mid-thigh), the standard-of-care in mela-
noma. False-positive lesions (determined by follow-up or pathology)
located in the legs were found in 1–3 % of the scans. Lesions below the
mid-thigh on 18F-FDG PET/CT were only true-positive in patients with
the primary melanoma on the lower extremities, clinical suspicion of
metastatic disease below the mid-thigh upfront or additional 18F-FDG
PET positive lesions in the torso FOV (Niederkohr et al., 2007; Davidson
and Sundram, 2011; Nguyen et al., 2007; Querellou et al., 2010; Lazaga
et al., 2013; Plouznikoff and Arsenault, 2017a, b). Taking these factors
into account for the individual patient, either a torso or true whole-
body FOV can be chosen.
In conclusion, overall, 18F-FDG PET/CT imaging is superior to ce-CT
in the detection of distant metastases in high-risk melanoma, except for
small pulmonary metastases. For the detection of brain metastases and
their therapeutic and prognostic consequences, MRI should be ad-
ditionally performed.
4. Clinical implications of 18F-FDG PET/CT for advanced
melanoma
Studies on the clinical impact of 18F-FDG PET/CT in patients with
stage III/IV disease report treatment changes in 13–74 % of the cases,
depending on the investigations already performed prior to the 18F-FDG
PET/CT (Pfannenberg et al., 2007; Reinhardt et al., 2006a; Bronstein
et al., 2012; Schüle et al., 2016; Subesinghe et al., 2013; Forschner
et al., 2017; Bastiaannet et al., 2009; Singnurkar et al., 2016; Falk et al.,
2007; Taghipour et al., 2017). Some studies compared treatment
changes after 18F-FDG PET/CT to an initial treatment plan based on
clinical information only, whereas others used a treatment plan based
on ce-CT with or without brain MRI or laboratory parameters as re-
ference. In a prospective study in 64 stage III/IV patients, treatment
changes (either from metastasectomy to systemic therapy or changes in
surgical approach or systemic treatment) were seen in 64 % of all pa-
tients after performance of 18F-FDG PET/ce-CT and wb-MRI, of which
90.2 % could be motivated by PET/ce-CT alone (Pfannenberg et al.,
2007). A prospective study in 107 patients with stage III/IV melanoma
evaluated treatment changes after an 18F-FDG PET/ce-CT was per-
formed to exclude new metastases (Forschner et al., 2017). All patients
were scheduled for radical metastasectomy, based on results of con-
ventional imaging and clinical and laboratory parameters. Conven-
tional imaging involved whole-body imaging by ce-CT and/or MRI in
66 % of the patients and local imaging such as ultrasound only in the
remainder. Treatment was changed after PET/ce-CT in 79 out of 107
patients (74 %), including 32 patients (30 %) in whom new and/or
inoperable metastases were found and who were re-allocated to sys-
temic therapy and/or palliative surgery. Precise changes within the
subgroup of stage IV patients (n = 57) and the specific cases in which
no prior imaging was done (34 % of total population) were not men-
tioned. More importantly, immunotherapy and BRAF inhibitors were
not standard treatment when these studies were performed and might
nowadays be favoured over surgery in patients with low tumour burden
(Ugurel et al., 2016).
In 2018, both immunotherapy and targeted therapy were approved
for adjuvant systemic treatment of patients with resected stage III
melanoma (Eggermont et al., 2018; Maio et al., 2018; Amaria et al.,
2018). The value of 18F-FDG PET/CT to rule out metastases before start
of adjuvant therapy, i.e. immediately after resection, has not yet been
evaluated. Adjuvant trials applied differing baseline imaging strategies
that did not always include 18F-FDG PET/CT, and most trials did not
report the number of patients that were excluded based on 18F-FDG
PET/CT findings (Eggermont et al., 2018; Maio et al., 2018; Amaria
et al., 2018; Bloemendal et al., 2019). The current best estimation of the
yield of 18F-FDG PET/CT in this setting is based on two recent imaging
studies in respectively clinically newly diagnosed stage IIIa-c melanoma
patients (n = 73) (Groen et al., 2019) and completely resected stage
IIIb/c melanoma patients within 6 weeks prior to adjuvant therapy (n
= 120) (Bloemendal et al., 2019). Upstaging or disease recurrence was
seen in 18 % of patients in both studies, but direct implications for the
use of 18F-FDG PET/CT are clouded by unmentioned scan interval
(Groen et al., 2019) and use of ce-CT scanning (96 % of cases) rather
than the more commonly applied 18F-FDG PET/nce-CT (Bloemendal
et al., 2019).
Whereas previous studies have shown that 18F-FDG PET/CT leads to
change in initial treatment plan in a substantial proportion of advanced
melanoma patients, the practical impact of 18F-FDG PET/CT in ad-
vanced melanoma needs to be re-evaluated for the current therapeutic
arsenal, i.e. including BRAF/MEK-inhibition, immunotherapy and ad-
juvant systemic treatment. A feasible first approach for the latter would
be describing the proportion of patients that are excluded from ad-
juvant treatment based on the screening with 18F-FDG PET/CT.
5. Monitoring treatment effects using 18F-FDG PET/CT
Treatment response in clinical studies is assessed using ce-CT-based
Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, which
have been validated for cytotoxic chemotherapy and targeted therapy
(Eisenhauer et al., 2009; Litière et al., 2019). For immunotherapy, ce-
CT-based response criteria require confirmation of progressive or newly
detected lesions on a subsequent scan before the patient is classified as
progressive. This confirmation minimizes the risk of falsely classifying
patients with pseudoprogression (< 10 % of patients), i.e. initial en-
largement before subsequent shrinkage of a responsive lesion caused by
immune cell influx (Borcoman et al., 2019). Numerous ce-CT response
criteria for immunotherapy have been developed (reviewed in
(Dimitrakopoulou-Strauss, 2019)). The iRECIST criteria, adapted from
RECIST 1.1 criteria, are recommended for uniform ce-CT response
evaluation in clinical trials on immunotherapy (Seymour et al., 2017).
At this time, data collection for formal validation of the iRECIST criteria
is ongoing.
For 18F-FDG PET/CT, the most commonly applied criteria for stan-
dardized and objective response measurement are those by the
European Organisation for Research and Treatment of Cancer (EORTC)
and the Positron Emission Tomography Response Criteria in Solid
Tumors (PERCIST) (Suppl. Table 3) (Young et al., 1999; Wahl et al.,
2009). These have not yet been validated on large uniform data sets.
18F-FDG PET/CT therapy monitoring showed no additional value in
chemotherapy response assessment when compared to the tumour
marker S100B and ld-CT in melanoma, although neither are regarded to
be the gold standard for response assessment (Hofman et al., 2007;
Strobel et al., 2008, 2007). Research now focuses on the use of 18F-FDG
PET/CT for predicting and monitoring (early) response and toxicity in
the current therapeutic landscape of immunotherapy and BRAF(/MEK)
targeted therapy (Suppl. Table 4) (Ribas et al., 2010; Sachpekidis et al.,
2014; Breki et al., 2016; Cho et al., 2017; Sachpekidis et al., 2018a;
Anwar et al., 2018; Sachpekidis et al., 2018b; Tan et al., 2018; Ito et al.,
2019a; Sachpekidis et al., 2019a; Amrane et al., 2019; McArthur et al.,
2012; Kraeber-Bodéré et al., 2012; Carlino et al., 2013; Falchook et al.,
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2014; Schmitt et al., 2016).
5.1. Monitoring immunotherapy using 18F-FDG PET/CT
The CTLA-4 inhibitor ipilimumab was the first immune checkpoint
inhibitor that received regulatory approval for treatment of advanced
melanoma (Hodi et al., 2010; Robert et al., 2011). A retrospective study
in 20 patients with metastatic melanoma, of which 16 were treated with
ipilimumab, analysed interim 18F-FDG PET/CT scans obtained 3−4
weeks after treatment start (Cho et al., 2017). At this early time-point,
the combination of RECIST CT response and SULpeak (SUVpeak normal-
ized by lean body mass) outperformed respectively single RECIST, im-
mune-related RECIST, PERCIST or EORTC response evaluation in pre-
dicting final best overall (RECIST) response after ≥four months
(accuracy of 95 % vs. 65–75 %). However, in an undefined subset ld-
CTs were used to determine response, while RECIST is only validated
for ce-CT, and in a later retrospective study the RECIST/SULpeak com-
bination was not able to predict PFS or OS (Amrane et al., 2019). In-
terestingly, in patients with RECIST stable disease at the interim scan (n
= 9), an increase in maximum SULpeak was associated with long-term
clinical benefit (Cho et al., 2017). This was hypothesized to be caused
by early influx of immune cells into the tumour, which have a high 18F-
FDG uptake in an activated state, and reflect pseudoprogression. In a
similar study (n = 22), two patients with a partial metabolic response
after four cycles of ipilimumab were also initially falsely classified as
progressive, based on lesion enlargement and higher SUVs on 18F-FDG
PET/CT after two cycles (Sachpekidis et al., 2014). In the same study,
18F-FDG PET/CT after two cycles correctly predicted progressive me-
tabolic disease (PMD) according to the EORTC criteria after completion
of four cycles in 13 out of 15 patients and stable metabolic disease
(SMD) in five out of five patients (Sachpekidis et al., 2014). Based on an
extended cohort (n = 41) with long-term follow-up (median 21.4
months) the authors proposed new PET Response Evaluation Criteria
for Immunotherapy (PERCIMT) centred around the number of new 18F-
FDG PET/CT-positive lesions. New lesions on the interim 18F-FDG PET/
CT scan after two cycles had a higher sensitivity than EORTC criteria (P
= 0.004) for predicting eventual treatment relapse, while specificity
did not differ (P = 0.5) (Sachpekidis et al., 2018a). In contrast to post-
therapy SUVmean and SUVmax changes of target lesions, emergence of
four or more new lesions on the 18F-FDG PET/CT scan performed im-
mediately after finishing four cycles of ipilimumab (compared to
baseline 18F-FDG PET/CT) was predictive of treatment failure (Anwar
et al., 2018; Sachpekidis et al., 2018b). Different immunotherapy-
modified PERCIST criteria (imPERCIST5) were suggested in a retro-
spective study of 60 metastatic melanoma patients treated with ipili-
mumab. In these imPERCIST5 criteria, new lesions on the 18F-FDG PET/
CT scan after treatment completion were included in total SUVpeak
measurements but did not define PMD per se, as is the case in PERCIST
criteria. Two-year OS was 66 % vs 29 % (P = 0.003) for patients with
and without an imPERCIST5-based response and 61 % vs 33 % (P =
0.028) for PERCIST criteria (Ito et al., 2019a). Other quantitative 18F-
FDG PET/CT studies evaluating dynamic (continuous tracer acquisi-
tion) and longitudinal (repetitive tracer acquisition) scanning did not
show additional value for prediction of ipilimumab responses (Breki
et al., 2016; Sachpekidis et al., 2018b, a). The studies performed so far
are based on small populations, do not take known prognostic factors
including lactate dehydrogenase (LDH) into account and/or lack stan-
dardized scan timing (Sachpekidis et al., 2014; Ito et al., 2019a). More
importantly, the applied 18F-FDG PET/CT criteria, including the EORTC
and PERCIST criteria that are used as standards, are unvalidated.
Whether 18F-FDG PET/CT response measurements have additional
value over conventional ce-CT-based (RECIST) evaluation is yet to be
determined.
The PD-1 immune checkpoint inhibitors pembrolizumab and nivo-
lumab showed superior clinical efficacy to chemotherapy and ipili-
mumab in phase III trials (Ribas et al., 2015; Robert et al., 2015; Weber
et al., 2015). One study in 27 melanoma patients investigated whether a
prolonged response to PD-1 inhibitors after> 12 months of treatment
could be characterized by the absence of metabolically active lesions on
18F-FDG PET/CT (Kong et al., 2016). 18F-FDG PET/CT scans were
performed at a median of 15.2 months (range 12–29 months) after
treatment initiation and showed metabolically active lesions in 15/27
patients (56 %). Biopsies were taken in eight patients with metaboli-
cally active lesions and revealed an immune cell infiltrate instead of
melanoma in three patients as the cause of 18F-FDG uptake. A trend
towards higher SUVmax values in the five patients with biopsy-proven
progression compared to the three patients with immune infiltrates
(median SUVmax 18 vs. 7.1) was observed. Interestingly, all twelve
patients without metabolically active lesions showed ongoing response
over the following six to 15 months, including five patients who
stopped treatment after the negative 18F-FDG PET/CT scan and six
patients who had residual lesions on the CT scan. A retrospective
analysis of 104 patients with stage IIIc/IV melanoma treated with PD-1
inhibitors +/- ipilimumab supports the complementary role for 18F-
FDG PET/CT to ce-CT in the decision to stop treatment after prolonged
response (Tan et al., 2018). Forty-seven of the 75 patients (63 %) with
RECIST partial response (PR) on ce-CT after one year had a complete
metabolic response (CMR) on corresponding 18F-FDG PET/CT. Patients
with both ce-CT PR and 18F-FDG PET/CT CMR had better one-year
progression-free survival than PR patients without CMR (100 % vs. 58
%, P<0.01). Seventy-five of 78 CMR patients (96 %) remained pro-
gression-free after treatment discontinuation, with a median follow-up
of 14.5 months.
The prognostic value of baseline quantitative 18F-FDG PET/CT
parameters for immunotherapy response was studied in 142 melanoma
patients treated with ipilimumab (Ito et al., 2019b). Of the baseline
parameters SULmax, SULpeak, whole-body MTV and total lesion glyco-
lysis (TLG; product of MTV and SUVmean), whole-body MTV was the
best independent prognostic factor for OS (P = 0.001). This remained
prognostic in a multivariate model including clinical parameters such as
LDH levels and presence of brain metastases. Other retrospective stu-
dies also show correlations between response or OS and quantitative
18F-FDG parameters, such as baseline intratumoural heterogeneity in
18F-FDG uptake (Sanli et al., 2019), baseline tumour SUVs, whole-body
MTV and TLG (de Heer et al., 2018; Seban et al., 2019), BLR (bone
marrow-to-liver SUVmax ratio) (Seban et al., 2019) or baseline physio-
logical 18F-FDG uptake of the colon (Boursi et al., 2019), although all
studies were complicated by low patient numbers (14–64 patients) and/
or heterogeneously treated populations.
Although the abovementioned studies have shown interesting re-
sults, such as the stronger correlation of PFS with 18F-FDG PET/CT
response than ce-CT response after one year, the evidence so far is
limited and based on small prospective cohorts and retrospective ana-
lyses. Consequently, there is currently no evidence to support the use of
18F-FDG PET/CT as a radiologic modality for response prediction and
response monitoring of immunotherapy in melanoma. Future large-
scale studies with standardized and well-described imaging protocols
are needed to enable sound comparisons. Critical aspects to include in
future studies are well-described homogeneous populations with stan-
dardized and repeated imaging (e.g. following EANM guidelines),
clearly defined response definitions, comparison of 18F-FDG PET/CT
with the current gold standard of ce-CT based (i)RECIST, histological
confirmation of metabolically active lesions to elucidate the phenom-
enon of pseudoprogression, and incorporation of clinical information,
such as symptoms and biomarkers of progression (e.g. LDH levels).
5.2. Monitoring systemic treatment with BRAF(/MEK)-targeted therapy
As opposed to immunotherapy, initiation of BRAF(/MEK) inhibitor
therapy can result in a rapid, massive reduction in tumour burden
(Sullivan and Flaherty, 2013). Several phase I studies describe no or
only a weak correlation between SUV reduction early after start of
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targeted therapy (approx. two weeks) and RECIST v1.0 CT response
after 8–12 weeks or survival (McArthur et al., 2012; Kraeber-Bodéré
et al., 2012; Falchook et al., 2014; Schmitt et al., 2016). This could be
partly explained by a previous observation in paired biopsies (n = 15)
that metabolic response on 18F-FDG PET/CT, measured as SUVmax de-
crease, reflects cell volume reduction and increased intercellular dis-
tance rather than cell death (Theodosakis et al., 2015). Interestingly,
absence of an early metabolic response was highly predictive of absent
RECIST response after 12 weeks, with a negative predictive value of 97
% (95 %-CI 86–100 %) (Kraeber-Bodéré et al., 2012). A heterogeneous
response after 15 days of treatment (i.e. lesions with metabolic response
alongside progressive or new lesions; 6/23 patients, 26 %) and<50 %
change in SUVmax of the least responsive tumour lesion were correlated
with shorter PFS but not OS (Carlino et al., 2013; Schmitt et al., 2016).
OS results may, however, be influenced by patients receiving im-
munotherapy after targeted therapy. LDH levels and ECOG performance
status, respectively, were also response predictors in the latter two
studies, but it was not studied whether PET parameters remain prog-
nostic when incorporating these variables into multivariate analyses.
These results imply that although 18F-FDG PET/CT is able to detect
an early metabolic response to BRAF and MEK inhibitors, this is not
predictive for subsequent RECIST response on ce-CT. The small number
of patients in these drug dose-escalating phase I trials and the inherent
dose differences among patients prevent making definitive conclusions.
Since clinical response is often clear and rapid the need for other early
response markers is limited. For future prospective studies in patients
treated with standard BRAF(/MEK) inhibitors it is of more interest to
determine whether 18F-FDG PET is able to detect resistance to BRAF
(/MEK) at an earlier time-point than CT-based RECIST progression or
clinical symptoms, which could aid in clinical decision making, for
instance in a timely switch to immunotherapy.
5.3. Detection of immune-related adverse events of systemic treatment on
18F-FDG PET/CT
Immune checkpoint inhibition can induce severe inflammatory re-
actions in normal organs and tissues. Inflamed tissue and active, in-
filtrating immune cells have a high glucose metabolism which results in
a high 18F-FDG uptake (Fig. 2). Colitis, for example, is a regularly ob-
served immune-related adverse event (irAE) of ipilimumab and clini-
cally characterised by diarrhoea (Hodi et al., 2010; Robert et al., 2011).
Radiologic manifestations of colitis on 18F-FDG PET/CT are an in-
creased focal or diffuse 18F-FDG uptake of the colonic wall and asso-
ciated thickening of the bowel wall on CT (Tirumani et al., 2015;
Bronstein et al., 2011; Wachsmann et al., 2017; Koo et al., 2014).
However, also normal bowel may show 18F-FDG uptake, e.g. in patients
on metformin, making the distinction with colitis challenging. In a
cohort of 100 patients with stage IV melanoma treated with ipili-
mumab, 18F-FDG PET/CT after two or four cycles showed signs of colitis
in 49 out of 100 patients (Lang et al., 2019). Only 21 (43 %) of these
developed symptoms (grade 1–3 diarrhoea) and in eight patients with
diarrhoea the 18F-FDG PET/CT was false-negative. It was not mentioned
whether the 18F-FDG PET/CT colitis diagnosis preceded clinical mani-
festations or expedited start of immunosuppressive therapy. In a ret-
rospective analysis of 17 melanoma patients who developed thyroid
dysfunction during pembrolizumab treatment, the 18F-FDG PET showed
diffuse thyroid 18F-FDG uptake in all patients with clinically detectable
thyroiditis (n = 7) (De Filette et al., 2016). Interestingly, 18F-FDG
uptake in the thyroid gland before treatment with nivolumab was a
significant predictor of overt thyroid irAEs (adjusted odds ratio of 14.48
[95 %-CI 3.12–67.19]), but not subclinical thyroid irAEs (Yamauchi
et al., 2019). Cases have been reported where 18F-FDG PET/CT scans
performed for treatment monitoring revealed immune-related adverse
events weeks before clinical symptoms became apparent (Tirumani
et al., 2015; Bronstein et al., 2011; Wachsmann et al., 2017; van der
Hiel et al., 2013; Mekki et al., 2018; van Willigen et al., 2019;
Calugareanu et al., 2019). These included hypophysitis, gastro-in-
testinal inflammation and inflammatory reactions of soft tissues such as
myositis or fasciitis and sarcoid-like lymphadenopathy.
An association between radiologically detected irAEs (by 18F-FDG
PET/CT or ce-CT) and response to anti-CTLA-4 therapy was shown in
119 patients with metastatic melanoma (Bronstein et al., 2011). Disease
control rate (i.e. radiological response and stable disease) was 55 % in
the group with (n = 20) and 10 % in the group without (n = 99)
radiologic manifestations of irAEs (P<0.0001). Additionally, sarcoid-
like lymphadenopathy on 18F-FDG PET/CT during ipilimumab treat-
ment was associated with clinical response (Sachpekidis et al., 2019b).
In contrast, neither signs of colitis on 18F-FDG PET/CT or symptoms of
diarrhoea correlated with best treatment response or OS (Lang et al.,
2019).
Generally, clinical information and/or biopsies of newly detected
lesions are still needed to differentiate between adverse events and
melanoma progression. Moreover, it is unclear in how many cases 18F-
FDG PET/CT can detect adverse events (long) before they become
clinically or biochemically manifest and whether this would alter
clinical management. Hence, evidence so far does not justify use of 18F-
FDG PET/CT for mere detection or monitoring of adverse events.
6. Discussion and future perspectives
The majority of studies on 18F-FDG PET/CT in melanoma have fo-
cused on detection of distant metastases in clinically stage I-III mela-
noma and complete staging of stage IV melanoma (Fig. 3). They in-
dicate that torso or whole-body 18F-FDG PET/CT is the most accurate
imaging work-up for staging in advanced melanoma when considering
non-cerebral metastases. Nevertheless, the current clinical con-
sequences of staging by 18F-FDG PET/CT + MRI brain, the current
standard in many melanoma centres, has thus far not been system-
atically compared to other imaging strategies.
Solid evidence justifying the use of 18F-FDG PET/CT for therapy
choices, monitoring and clinical decision-making regarding early sys-
temic therapy stopping or switching is lacking (Fig. 3). Limited data
suggests that 18F-FDG PET/CT might aid in expedited detection of non-
responders to BRAF-/MEK-inhibition and could be useful in predicting
in which long-term responders to anti-PD-1-therapy this response will
be persistent. The correlation of long-term outcomes with early 18F-FDG
PET/CT response after start of BRAF-/MEK-inhibition or im-
munotherapy is disappointing. Several ongoing and planned 18F-FDG
PET/CT studies addressing these and other questions are currently re-
gistered at ClinicalTrials.gov (Table 1).
So far, RECIST response measurement by ce-CT remains the cur-
rently best available gold standard. Therefore, a baseline reference ce-
CT is still required to eventually determine response according to va-
lidated criteria. It currently remains unclear whether 18F-FDG PET/CT
can detect disease progression earlier than conventional imaging using
ce-CT, facilitating a timely switch of treatment strategy when applic-
able. The high number of patients that are falsely classified as re-
sponders, insufficient understanding of the significance of new or pro-
gressive metabolically active lesions and mixed responses pose the same
challenges as with ce-CT response monitoring. More importantly, in-
terpretation of the studies performed so far is clouded by small het-
erogeneous populations without validation cohorts, absence of studies
on anti-PD-1-therapy, inconsistent scan timing, the use of various non-
validated sets of response criteria and insufficient information on use of
accredited systems and adherence to harmonization guidelines (e.g.
EANM Research Ltd. [EARL]). Strict adherence to uniform scan proto-
cols and detailed descriptions hereof is vital for evaluating existing and
novel proposed 18F-FDG PET/CT response measures and the potential
complementary role of 18F-FDG PET/CT to current ce-CT-based re-
sponse measurement. The lack of these uniform and well-described
studies so far has prevented pooled meta-analyses of large-scale study
cohorts that are required for validation and implementation of 18F-FDG
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PET/CT measurements in existing response criteria (Litière et al.,
2017). Initiatives are ongoing to provide practical protocols and aids for
performing and describing (quantitative) 18F-FDG PET/CT studies to
facilitate such large-scale analyses and validation in the future (RECIST
Working Group, 2020; Kinahan et al., 2020). Meanwhile, novel PET
tracers that are thought to be more specific than 18F-FDG for evaluating
immunotherapy response in melanoma are rapidly being developed.
Approaches that are currently investigated in preclinical models or in
early phase clinical trials include novel PET tracers that bind to mel-
anin, immune checkpoints or CD8+ T cells (Dimitrakopoulou-Strauss,
2019; Gilardi et al., 2014; Pandit-Taskar et al., 2020; Bensch et al.,
2018).
Radiation burden and cost-effectiveness are important when con-
sidering incorporation of 18F-FDG PET/CT scanning into clinical prac-
tice. Lifetime attributable risk estimates for cancer incidence following
exposure to 10 mSv are highly age- and gender-dependent, with young
Fig. 2. Appearance of various immune-related adverse events in patients with metastatic melanoma treated with immunotherapy on 18F-FDG PET/CT. (Patient
drawing adjusted from Wikimedia Commons [Internet] (2020)).
Fig. 3. Overview of relevant referenced studies (dots) and the value of 18F-FDG PET/CT (squares) during the disease course of advanced melanoma. Studies are
depicted according to their Level of Evidence (OCEBM Levels of Evidence Working Group, 2011) and (main) topic. Subsequent interpretation of the final value of 18F-
FDG PET/CT for each timeframe has been based on overall conclusions of the studies and their LoE. 18F-FDG PET/CT = 18F-fluorodeoxyglucose positron emission
tomography/computed tomography, LoE = Level of Evidence.
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females being especially sensitive to radiation (Wall et al., 2011).
Young melanoma patients are relatively common and the number of
follow-up scans has increased with increasing numbers of long-term
survivors. Although radiation exposure of an 18F-FDG PET/CT scan is
approximately two-fold lower than of ce-CT, as mentioned earlier, de-
liberate application remains indicated for this reason as well.
The three existing studies addressing economic evaluation of 18F-
FDG PET/CT scans do not include immunotherapy and targeted therapy
as possible treatment options, are based on outdated cost information
(e.g. from 1996) and/or PET-only technology or have a merely hy-
pothetical economic model (Bastiaannet et al., 2012; Krug et al., 2010;
Buck et al., 2010). It is likely that cost-effectiveness analyses will turn
out differently nowadays, considering the decreasing costs of integrated
18F-FDG PET/CT, the high costs of immunotherapy and targeted
therapy, and the prolonged survival of responders which increases
follow-up surveillance time. Key questions for novel cost-effectiveness
analyses are whether 18F-FDG PET/CT scanning diminishes or increases
the number of additional diagnostic procedures and whether baseline
18F-FDG PET/CT scanning contributes to better decision-making be-
tween different systemic therapies by identifying patients with highest
response chances upfront.
In conclusion, 18F-FDG PET/CT has a clear role during diagnostic
work-up in advanced melanoma and well-designed studies will aid in
determining whether it is rational to also include 18F-FDG PET/CT
during treatment and follow-up of patients with metastatic melanoma.
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